EI

231.3

+0.13%↑

MRK1

137.9

-0.25%↓

SHL.DE

52.04

-0.88%↓

ARGX

606

+1.2%↑

UCB

185.9

+0.68%↑

EI

231.3

+0.13%↑

MRK1

137.9

-0.25%↓

SHL.DE

52.04

-0.88%↓

ARGX

606

+1.2%↑

UCB

185.9

+0.68%↑

EI

231.3

+0.13%↑

MRK1

137.9

-0.25%↓

SHL.DE

52.04

-0.88%↓

ARGX

606

+1.2%↑

UCB

185.9

+0.68%↑

EI

231.3

+0.13%↑

MRK1

137.9

-0.25%↓

SHL.DE

52.04

-0.88%↓

ARGX

606

+1.2%↑

UCB

185.9

+0.68%↑

EI

231.3

+0.13%↑

MRK1

137.9

-0.25%↓

SHL.DE

52.04

-0.88%↓

ARGX

606

+1.2%↑

UCB

185.9

+0.68%↑

Search

Sanofi SA

Cerrado

Sector Salud

91.5 0.1

Resumen

Variación precio

24h

Actual

Mínimo

91.38

Máximo

91.61

Métricas clave

By Trading Economics

Ingresos

1.7B

2.8B

Ventas

2.1B

13B

P/B

Media del Sector

30.62

87.008

BPA

2.86

Rentabilidad por dividendo

3.944

Margen de beneficio

20.945

EBITDA

2.2B

4.2B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+21.17 upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.94%

2.48%

Próximas Ganancias

30 ene 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

111B

Apertura anterior

91.4

Cierre anterior

91.5

Noticias sobre sentimiento de mercado

By Acuity

25%

75%

69 / 392 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

Sanofi SA Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

20 dic 2024, 08:29 UTC

Adquisiciones, fusiones, absorciones

Santander to Sell Stake in Credit Agricole's Caceis Back to French Bank -- Update

20 dic 2024, 06:40 UTC

Adquisiciones, fusiones, absorciones

Santander to Sell Stake in Credit Agricole's Caceis Back to French Bank

17 dic 2024, 19:39 UTC

Principales Movimientos del Mercado

Correction to Teva Articles

17 dic 2024, 16:24 UTC

Principales Movimientos del Mercado

Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment

15 nov 2024, 10:28 UTC

Principales Movimientos del Mercado

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

29 oct 2024, 10:07 UTC

Ganancias

Santander's Profit Beats Expectations on Lower Provisions, Costs -- Update

29 oct 2024, 06:37 UTC

Ganancias

Santander's Profit Beats View Despite Lower-Than-Expected Revenue

20 dic 2024, 12:10 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Santander's Caceis Stake Disposal Could Open Door to Similar Transactions -- Market Talk

12 dic 2024, 11:20 UTC

Charlas de Mercado

Goldman Selectively Constructive on European Banks -- Market Talk

25 nov 2024, 09:15 UTC

Charlas de Mercado

Sanofi's U.S. Hospital Drug-Discount Program Seems Positive But Rollout Hurdles Remain -- Market Talk

22 nov 2024, 22:20 UTC

Principales Noticias

Sanofi Plans to Change Hospital Drug-Discount Program -- 3rd Update

22 nov 2024, 16:39 UTC

Principales Noticias

Sanofi Plans to Change Hospital Drug-Discount Program -- 2nd Update

22 nov 2024, 16:34 UTC

Principales Noticias

Sanofi Plans to Change Hospital Drug-Discount Program -- Update

22 nov 2024, 16:26 UTC

Principales Noticias

Sanofi Plans to Change Hospital Drug-Discount Program -- WSJ

22 nov 2024, 10:55 UTC

Charlas de Mercado

Spain's New Banking Tax Offers Headache for Some, Relief for Others -- Market Talk

22 nov 2024, 10:38 UTC

Charlas de Mercado

Spain's New Bank Levy to Weigh on Three Largest Lenders -- Market Talk

15 nov 2024, 13:08 UTC

Principales Noticias

Trump's RFK Pick Weighs on Vaccine Makers -- WSJ

15 nov 2024, 10:34 UTC

Charlas de Mercado

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

15 nov 2024, 10:29 UTC

Acciones populares

Stocks to Watch Friday: Tesla, Domino's, Palantir, Ulta -- WSJ

14 nov 2024, 11:29 UTC

Charlas de Mercado
Ganancias

European Banks' Results Confirm Earnings Momentum -- Market Talk

4 nov 2024, 11:42 UTC

Charlas de Mercado

European Banks Exposed to Trade Tariffs Outcome From U.S. Election -- Market Talk

29 oct 2024, 13:16 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Conditions Lack for Attractive European Cross-Border M&A Deals, Santander CEO Says -- Market Talk

29 oct 2024, 07:02 UTC

Charlas de Mercado

Santander's Take on Brazil Rates, Motor-Finance Issue in Focus -- Market Talk

29 oct 2024, 05:52 UTC

Ganancias

Santander Backs 2024 View

29 oct 2024, 05:52 UTC

Ganancias

Santander: If All Targets Are Met, Total Remuneration Against 2024 Results Over EUR6B

29 oct 2024, 05:51 UTC

Ganancias

Santander Confident on Delivering on Targets

29 oct 2024, 05:50 UTC

Ganancias

Analysts Saw Santander End-3Q Fully Loaded CET1 Ratio 12.5%

29 oct 2024, 05:50 UTC

Ganancias

Santander End-3Q Fully Loaded CET1 Ratio 12.5%

29 oct 2024, 05:49 UTC

Ganancias

Analyst Saw Santander 3Q Net Interest Income EUR11.59B

29 oct 2024, 05:49 UTC

Ganancias

Santander 3Q Net Interest Income EUR11.225B

Comparación entre iguales

Cambio de precio

Sanofi SA Esperado

Precio Objetivo

By TipRanks

21.17% repunte

Estimación a 12 meses

Media 110.601 EUR  21.17%

Máximo 123 EUR

Mínimo 85 EUR

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sanofi SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

12 ratings

8

Comprar

3

Mantener

1

Vender

Puntuación técnica

By Trading Central

91.05 / 91.53Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

69 / 392 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Sanofi SA

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.